Why growth oil trial results matter for careful shoppers

Fifty-seven point seven three percent is the figure to hold in mind, from a 90 day randomized test of a rosemary and lavender oil that was reported ahead of 10 September 2026 and followed a June 2026 guide. Two older studies had already set rosemary against minoxidil 2%, and more recent work has looked at peptides, low dose oral minoxidil and regenerative care.

A 2015 randomization by Panahi and colleagues assigned 100 people with androgenetic alopecia to rosemary oil or minoxidil 2% across six months. Each arm recorded a significant rise in hair count from the starting point, without a significant gap between arms. Itch of the scalp appeared more often with minoxidil, at 44.4% compared with 15% for rosemary, and dandruff also appeared more often with minoxidil, at 32.2% compared with 7.5% for rosemary.

A 2020 randomization by Nasirian and colleagues assigned 60 participants to 2% rosemary oil or 2% minoxidil for 24 weeks. Counts grew 10% with rosemary and 13% with minoxidil, at p equals 0.12. The close call still matters, and the solid win matters as well. Those studies tested minoxidil at 2%, not the stronger 5% preparation used by many adults, so similarity there does not show sameness with present usual dosing.

The latest rosemary evidence combines the plant with lavender alongside a control group. A 2025 randomization by Patel and colleagues placed 90 participants on rosemary-lavender oil, a peptide preparation or control for 90 days. The rosemary-lavender group lifted hair growth rate by 57.73% against control at p less than 0.0001. That same group lifted thickness by 68.70% and density by about 32% against control, while shedding dropped by more than 40%.

Bench research suggests one possible mechanism. Murata and colleagues reported in 2013 that rosemary leaf extract blocked 5-alpha reductase by 82.4% at 200 ug per mL and 94.6% at 500 ug per mL in vitro. In that same test finasteride produced 81.9% blocking. What works in glass does not always predict what works on skin.

Peptides remain earlier in the evidence root system. A phase 2A trial of PP405, a peptide that wakes hair follicle stem cells, saw statistically significant regrowth at eight weeks in 78 patients. A telogen effluvium study recruited 45 subjects aged 18 to 45 years into three sets of 15 for 90 days, assessing Capilia longa combinations, cytokine and peptide combinations, and redensyl with aminexil at 2 mL once daily. Sample sizes are small, tracking is brief and formulas differ.

Low dose oral minoxidil is shifting from office habit toward shared rules. An international consensus on starting and monitoring earned 4th place as a poster at the 2024 American Academy of Dermatology Annual Meeting. It showed daily ranges of 0.625 to 2.5 mg for adolescent females, 0.625 to 5 mg for adult females, and 1.25 to 5 mg for adolescent and adult males. Visible benefit usually shows between 3 to 6 months. That advice rests on expert consensus because larger trials are limited. A pooled review found platelet rich plasma clearly raised hair count and density against controls. “Regenerative options like PRP are now a core part of how we treat early hair loss, since they use the body’s own repair signals,” said Dr. Lindsay Bordone, MD, FAAD, dermatologist at Columbia University and the American Academy of Dermatology.

For a low maintenance routine, the compromise is clear. Rosemary needs daily use and patience, with less itching in these trials but no proof of durable regrowth after stopping. It remains unclear if retail oils equal standardized formulas or equal minoxidil 5% over 12 months.

Look out for bigger trials testing standard 5% dosing, listed peptide amounts and extended follow up.